SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-107561
Filing Date
2021-04-06
Accepted
2021-04-06 16:02:09
Documents
15
Period of Report
2021-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d22360d8k.htm   iXBRL 8-K 33962
2 EX-1.1 d22360dex11.htm EX-1.1 173501
3 EX-3.1 d22360dex31.htm EX-3.1 71130
4 EX-5.1 d22360dex51.htm EX-5.1 5397
  Complete submission text file 0001193125-21-107561.txt   482437

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ctic-20210331.xsd EX-101.SCH 3093
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20210331_lab.xml EX-101.LAB 18889
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20210331_pre.xml EX-101.PRE 11875
8 EXTRACTED XBRL INSTANCE DOCUMENT d22360d8k_htm.xml XML 3598
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 21809211
SIC: 2834 Pharmaceutical Preparations